Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PR1 Vaccine and GM-CSF for Low/Int-1 MDS
NCT00513578Phase 2Unknown
- Sponsor
- Vaccine Company
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Countries
- 1
01
Overview
A Phase 2 trial of PR1 leukemia peptide vaccine in myelodysplastic syndrome (MDS), sponsored by Vaccine Company. Status: unknown.
02
Drugs
PR1 leukemia peptide vaccine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00513578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00513578.